1Y Close · As of Aug 26, 2026
ADBIOTECH operates in the Pharmaceuticals sector.
Legal name: ADBIOTECH Co.,Ltd.
In fiscal year 2025, ADBIOTECH (179530) reported revenue of 12.9 billion KRW, up 15.8% from 11.1 billion KRW a year earlier.
Operating profit was -3.5 billion KRW and net income was -3.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 65.4 billion KRW, with a P/B of 4.83.
These figures can be verified in the DART filing (receipt no. 20260323000601).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 12.9B | -3.5B | -3.3B |
| 2024 | 11.1B | -4.1B | -9.0B |
| 2023 | 10.5B | -4.8B | -5.4B |
Recent Filings
CEO Change
Semi-Annual Report (2026.06)
Independent Director Change Report
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-20 | CEO Change |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-12 | Independent Director Change Report |
| 2026-08-11 | Extraordinary Meeting Result |